Enterprise Value
-194.6M
Cash
409.4M
Avg Qtr Burn
-61.01M
Short % of Float
5.77%
Insider Ownership
1.07%
Institutional Own.
97.38%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rezpegaldesleukin (NKTR-358) Details Autoimmune disease, Atopic dermatitis | Phase 2b Data readout | |
NKTR-255 + Avelumab Details Urothelial carcinoma, Cancer | Phase 2 Data readout | |
Rezpegaldesleukin (NKTR-358) Details Autoimmune disease, Alopecia areata | Phase 2a Initiation | |
NKTR-255 (IL-15R agonist) + Cetuximab (Erbitux) (EGFR inhibitor) Details Colorectal cancer , Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Data readout | |
NKTR-255 (IL-15 agonist) + Daratumumab Details Non-Hodgkin lymphoma, Multiple myeloma, Cancer | Phase 1/2 Data readout | |
NKTR-255 (IL-15 agonist) + C-TIL051 Details Cancer, Non-small cell lung carcinoma | Phase 1 Data readout | |
Bempegaldesleukin (NKTR-214) + Opdivo (Nivolumab) Details Renal cell carcinoma, Cancer | Failed Discontinued | |
Rezpegaldesleukin (LY3471851) (NKTR-358) Details Autoimmune disease, Systemic lupus erythematosus | Failed Discontinued | |
Bempegaldesleukin (NK-214) + VB10.NEO Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued | |
NKTR-358 Details Autoimmune disease, Ulcerative colitis | Failed Discontinued | |
Bempegaldesleukin (NKTR-214)+ OPDIVO (Nivolumab) Details Urothelial cancer, Cancer, Bladder cancer | Failed Discontinued | |
Dapirolizumab Pegol (anti-CD40L) Details Systemic lupus erythematosus, Autoimmune disease | Failed Discontinued | |
Bempegaldesleukin (NKTR-214)+ Opdivo (Nivolumab) Details Bladder cancer, Cancer | Failed Discontinued | |
Bempegaldesleukin (NKTR 214) + Opdivo (Nivolumab) Details Cancer, Melanoma | Failed Discontinued | |
Onzeald (etirinotecan pegol) Details Metastatic breast cancer to brain, Cancer | Failed Discontinued | |
Bempegaldesleukin (BEMPEG) + KEYTRUDA (pembrolizumab) Details Head and neck cancer, Cancer | Failed Discontinued | |
NKTR-262 (with bempegaldesleukin) Details Solid tumor/s, Cancer | Failed Discontinued | |
Bempegaldesleukin (NKTR-214) + OPDIVO (Nivolumab) Details Solid tumor/s, Cancer | Failed Discontinued | |
Bempegaldesleukin+ KEYTRUDA® (pembrolizumab) (PROPEL) Details Non-small cell lung carcinoma, Cancer | Failed Discontinued |